MOLECULAR STUDY THE COMBINATION OF JBJ-04-125-02 AND OSIMERTINIB AS INHIBITORS OF DOUBLE MUTANT (T790M/V948R) AND TRIPLE MUTANT (T790M/C797S/V948R) EGFR MUTANTS AT ALLOSTERIC SITES AND ATP SITES
The most common type of lung cancer is the Non-Small Cell Lung Cancer (NSCLC) type, accounting for 80-85% of the total lung cancer sufferers in the world. Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor (EGFR-TKI) is recommended as first-line treatment of advanced EGFR-mutant NSCL...
Saved in:
Main Author: | Rachmawati, Fithriana |
---|---|
Format: | Theses |
Language: | Indonesia |
Online Access: | https://digilib.itb.ac.id/gdl/view/76566 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Institut Teknologi Bandung |
Language: | Indonesia |
Similar Items
-
HOMOLOGY MODELING OF EGFR MUTATED L858R/T790M/C797S
by: Alif Aditya, Faris -
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
by: Shimamura, T, et al.
Published: (2020) -
Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression
by: Janpipatkul K.
Published: (2023) -
Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
by: Suriya U.
Published: (2023) -
Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report
by: Boongird A.
Published: (2023)